Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Hazard ratios of joint ER and PR tumors per 5 cm increase in BMI across each age band among all women and never users of HRT.

From: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

  ≤49
years
Between
50 and 54 years
Between
55 and 59 years
Between
60 and 64 years
≥65
years
  Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI
All women               
Age and center stratified               
ER+PR+ 390 0.79 (0.68-0.91) 698 0.88 (0.79-0.97) 830 1.08 (0.69-1.06) 806 1.05 (0.96-1.14) 862 1.25 (1.16-1.34)
ER+PR- 64 1.10 (0.81-1.50) 180 0.86 (0.69-1.06) 306 0.86 (0.68-1.38) 280 0.86 (0.74-1.01) 256 0.92 (0.78-1.08)
ER-PR+ 71 0.68 (0.47-0.99) 57 0.97 (0.68-1.38) 37 0.55 (0.91-1.27) 31 0.83 (0.50-1.37) 17 0.70 (0.35-1.42)
ER-PR- 147 0.89 (0.72-1.12) 217 1.08 (0.91-1.27) 244 0.98 (0.93-1.13) 217 0.95 (0.80-1.12) 196 0.95 (0.79-1.13)
ER or PR missing 533 0.92 (0.82-1.03) 618 1.03 (0.93-1.13) 734 1.03 (1.00-1.18) 731 1.02 (0.94-1.11) 1008 1.09 (1.01-1.17)
P heterogeneity 2    0.36    0.05    0.26    0.28    0.004
Multivariable model 4               
ER+PR+ 390 0.80 (0.69-0.93) 698 0.90 (0.81-1.01) 830 1.11 (1.01-1.21) 806 1.10 (1.01-1.20) 862 1.32 (1.22-1.43)
ER+PR- 64 1.14 (0.83-1.55) 180 0.90 (0.72-1.12) 306 0.90 (0.76-1.05) 280 0.88 (0.75-1.03) 256 0.97 (0.82-1.14)
ER-PR+ 71 0.67 (0.46-0.99) 57 0.98 (0.68-1.40) 37 0.57 (0.32-1.01) 31 0.84 (0.50-1.43) 17 0.79 (0.37-1.68)
ER-PR- 147 0.90 (0.71-1.13) 217 1.09 (0.92-1.29) 244 1.00 (0.84-1.18) 217 0.97 (0.81-1.16) 196 0.97 (0.81-1.17)
ER or PR missing 533 0.93 (0.83-1.05) 618 1.08 (0.98-1.19) 734 1.08 (0.99-1.18) 731 1.06 (0.97-1.16) 1008 1.13 (1.05-1.22)
P heterogeneity 2    0.44    0.08    0.29    0.20    0.002
HRT never users               
Age and center stratified               
ER+PR+        350 1.10 (0.97-1.25) 348 1.08 (0.96-1.22) 441 1.34 (1.22-1.47)
ER+PR-        135 0.87 (0.69-1.10) 118 0.95 (0.76-1.19) 138 0.96 (0.78-1.18)
ER-PR+        16 0.63 (0.28-1.40) 10 0.74 (0.30-1.79) 8 0.98 (0.42-2.29)
ER-PR-        95 1.12 (0.88-1.42) 90 1.05 (0.83-1.33) 105 1.06 (0.85-1.32)
ER or PR missing        304 1.06 (0.94-1.21) 325 1.08 (0.96-1.22) 566 1.13 (1.03-1.24)
P heterogeneity 2          0.94    0.83    0.05
Multivariable model 5               
ER+PR+        350 1.11 (0.97-1.27) 348 1.13 (1.00-1.28) 441 1.38 (1.25-1.52)
ER+PR-        135 0.91 (0.72-1.15) 118 0.96 (0.76-1.21) 138 1.02 (0.83-1.25)
ER-PR+        16 0.62 (0.26-1.49) 10 0.63 (0.24-1.67) 8 1.06 (0.37-3.03)
ER-PR-        95 1.19 (0.93-1.54) 90 1.09 (0.85-1.40) 105 1.11 (0.88-1.39)
ER or PR missing        304 1.09 (0.96-1.24) 325 1.11 (0.98-1.25) 566 1.17 (1.06-1.28)
P heterogeneity 2          0.62    0.83    0.08
  1. 1Per 5 kg/m2 increase; 2heterogeneity between ER+PR+ versus ER-PR- tumors using data augmentation method as described by Lunn and McNeil; 3multivariable hazard ratios were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, age at menarche, menopausal status, age at menopause (in postmenopausal women), ever OC use and current HRT use; 4multivariable hazard ratios were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, age at menarche, ever OC use, menopausal status, age at menopause (in postmenopausal women). BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy; PR, progesterone receptor.